Recursion Pharmaceuticals Inc vs Sibanye Stillwater Ltd — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Sibanye Stillwater Ltd trades at $10.72 (market cap $7.54B). The key difference: Sibanye Stillwater Ltd is far larger — about 4.2× Recursion Pharmaceuticals Inc's market cap, and Sibanye Stillwater Ltd pays a 2.93% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SBSW | |
|---|---|---|
Market Cap | $1.81B | $7.54B |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $21.12 |
52-Week Low | $2.84 | $7.27 |
Enterprise Value | $1.33B | $9.19B |
Dividend Yield | — | 2.93% |
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Sibanye Stillwater (SBSW) trades at $10.67, up 0.28% with a bullish technical signal despite recent earnings misses. The stock shows attractive valuation metrics with P/E of 4.76 and P/S of 0.94, though profitability remains challenged with negative net income margin of -3.99%. Recent news highlights significant price volatility and mixed analyst views on valuation.
The outlook suggests potential upside to the $14.25 consensus price target, supported by projected cash flow improvement in 2025. Key risks include persistent negative earnings, high debt levels, and commodity price sensitivity. Institutional sentiment leans bullish with 43% buy ratings, but investors should monitor execution on debt reduction targets.
Trailing returns across standard periods
Latest headlines on both assets
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →